Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 135 Route 202/206, Suite 6 BEDMINSTER NJ 07921 |
Tel: | N/A |
Website: | https://www.intracellulartherapies.com |
IR: | See website |
Key People | ||
Sharon Mates Chairman of the Board, Chief Executive Officer | Michael I. Halstead President | Sanjeev Narula Chief Financial Officer, Executive Vice President |
Suresh K. Durgam Executive Vice President, Chief Medical Officer | Mark Neumann Executive Vice President, Chief Commercial Officer |
Business Overview |
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity. |
Financial Overview |
For the nine months ended 30 September 2024, Intra-Cellular Therapies Inc revenues increased 45% to $481.6M. Net loss decreased 48% to $57.8M. Revenues reflect Biopharmaceutical segment increase from $237M to $481.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.16 to -$0.56. |
Employees: | 610 as of Feb 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7,957M as of Sep 30, 2024 |
Annual revenue (TTM): | $613.73M as of Sep 30, 2024 |
EBITDA (TTM): | -$121.09M as of Sep 30, 2024 |
Net annual income (TTM): | -$86.37M as of Sep 30, 2024 |
Free cash flow (TTM): | -$62.86M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 106,017,103 as of Oct 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |